Aberdeen Group plc Has $7.71 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Aberdeen Group plc increased its stake in NewAmsterdam Pharma by 110.5% in Q1, owning approximately $7.71 million worth of shares.
• Equity analysts are optimistic, with multiple firms setting price targets between $27.00 and $44.00, and a consensus rating of "Moderate Buy".
• Insider trading activity included COO Douglas F. Kling selling 100,000 shares and Director James N. Topper purchasing 8,584 shares, reflecting significant movement in ownership interests.

Aberdeen Group plc lifted its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 110.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 376,863 shares of the company's stock after purchasing an additional 197,803 shares during the period. Aberdeen Group plc owned about 0.34% of NewAmsterdam Pharma worth $7,714,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. lifted its position in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after acquiring an additional 596 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after acquiring an additional 3,390 shares during the last quarter. Avanza Fonder AB purchased a new stake in NewAmsterdam Pharma during the first quarter valued at approximately $127,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $221,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

NAMS traded up $0.49 during trading on Tuesday, hitting $25.19. The company had a trading volume of 1,261,007 shares, compared to its average volume of 795,733. The company has a market cap of $2.84 billion, a PE ratio of -15.55 and a beta of -0.02. The business has a 50-day moving average of $21.93 and a 200-day moving average of $20.27. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The firm had revenue of $19.15 million for the quarter, compared to analysts' expectations of $1.44 million. Research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In related news, Director James N. Topper acquired 8,584 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, June 16th. The stock was acquired at an average price of $19.50 per share, with a total value of $167,388.00. Following the completion of the acquisition, the director directly owned 3,022,153 shares of the company's stock, valued at $58,931,983.50. This trade represents a 0.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares of the company's stock, valued at $2,897,845.58. The trade was a 29.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders bought 12,835 shares of company stock worth $248,134 and sold 248,612 shares worth $5,240,387. Insiders own 20.84% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday. They set an "overweight" rating and a $45.00 price target on the stock. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $41.55.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.